tbuckley/cabot-search huggingface dataset:
Imatinib-Based Chemotherapy for Newly Diagnosed BCR–ABL Positive Acute Lymphoblastic Leukemia: Japan Adult Leukemia Study Group (JALSG) Ph+ALL208 Study
Authors: Shin Fujisawa, Keitaro Matsuo, Shuichi Mizuta, Hideki Akiyama, Yasunori Ueda, Yasutaka Aoyama, Yoshihiro Hatta, Kazuhiko Kakihana, Nobuaki Dobashi, Isamu Sugiura, Yasushi Onishi, Tomoya Maeda, Kiyotoshi Imai, Shigeki Ohtake, Yasushi Miyazaki, Kazunori Ohnishi, Tomoki Naoe
Journal: Blood (2014)
Ombitasvir/Paritaprevir/Ritonavir with Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egyptian Adults with Chronic HCV Genotype 4 Infection (Agate-II)
Authors: I. Waked, G. Shiha, R.B. Qaqish, G. Esmat, A. Yosry, W. Doss, M. Hassany, R. Soliman, M.A. Mohey, N. Allam, N. Zayed, C.M. Setze, R. Redman, N. Mobashery
Journal: Journal of Hepatology (2016)
Natural History and Management of Esophagogastric Varices in Chronic Non-Cirrhotic Non-Tumoral Portal Vein Thrombosis
Authors: C.N. Ferreira, S. Seijo, A. Plessier, G. Silva-Junior, F. Turon, P.-E. Rautou, A. Baiges, C. Bureau, J. Bosch, V. Hernández-Gea, D. Valla, J.C. Garcia-Pagan
Journal: Journal of Hepatology (2016)
Hepatic Fibrosis Measured by Elastography among People who Inject Drugs with Chronic HCV in Community Settings: The Tap Study
Authors: J.S. Doyle, P. Dietze, P. Desmond, D.M. Iser, M. Stoove, E. McBryde, P. Higgs, M.E. Hellard, A.J. Thompson
Journal: Journal of Hepatology (2016)
Effects of different PKC isoforms on proliferation, survival and invasiveness in a human pancreatic carcinoma cell line (PANC-1)
Authors: Valeria C. Grossoni, Laura V. Mauro, Alejandro J. Urtreger, Marcelo G. Kazanietz, Elisa Bal de Kier Joffé, Lydia I. Puricelli
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

3517 

PKCs constitute a serin-threonin kinase family that have a key role in malignant transformation. The functional relevance of each PKC isoform is unclear, because of their differential expression in different tissues. Pancreatic carcinoma is characterized by poor prognosis and lack of response to conventional therapy. The ethiology of this disease is almost unknown. The aim of this work was to study the effect of PKC delta (δ) and PKC zeta (ζ) overexpression on in vitro properties associated with the tumoral behavior of the human pancreatic cancer cells, PANC-1. In every case, cells transfected with the empty vectors were used as controls (C). The invasive ability of PANC-1 cells, assessed in matrigel-coated transwell chambers, was inhibited by the overexpression of PKCδ and enhanced by PKCζ (PKCζ: 12.54±1.8 vs C: 6.53±0.8 invasive cells/field, p<0.05; PKCδ: 3.01±1.2, vs C: 11.44±3.3 cells/field, p<0.05). In the case of PKCδ this behavior was associated with a decrease in MMPs activity, while uPA secretion was not modulated. On the other hand, neither uPA nor MMPs seemed to be involved in the higher invasive ability of PANC-PKCζ cells. While overexpression of PKCζ promoted the clonogenic ability of PANC-1 cells, PKCδ showed no effect on this property. Finally we demonstrated that neither PANC-δ or PANC-PKCζ cells differ from control cells in their susceptibility to cytotoxicity induced by doxorrubicin. However, when PANC-PKCδ cells were exposed to the phorbol ester PMA, cells became resistant to the cytotoxic treatment. Our results suggest that the overexpression of PKCζ induced a more malignant phenotype associated with the enhancement in invasiveness and clonogenicity. On the contrary, PKCδ overexpression was associated with a more normal phenotype due to the decrease in the proteolytic secretion and in consequence in invasiveness.
The MLL Recombinome of Adult ALL - Results from the GMALL Study Group.
Authors: Thomas Burmeister, Claus Meyer, Stefan Schwartz, Daniela Hubert, Mara Molkentin, Eric Kowarz, Nicola Goekbuget, Dieter Hoelzer, Rolf Marschalek, Eckhard Thiel
Journal: Blood (2007)
Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program
Authors: J. Petersen, T. Welzel, K. Herzer, P. Ferenci, M. Gschwantler, M. Cornberg, P. Ingiliz, T. Berg, U. Spengler, O. Weiland, M. van der Valk, H. Klinker, J. Rockstroh, M. Peck-Radosavljevic, Y. Zhao, M.J. Jimenez-Exposito, S. Zeuzem
Journal: Journal of Hepatology (2016)
Combination of intensity-modulated radiation therapy (IMRT) and a heavy ion (C12) boost for subtotal resected or inoperable adenoid cystic carcinomas (ACCs) of the head and neck region.
Authors: M. Muenter, V. Umathum, A. D. Jensen, A. Nikoghosyan, H. Hof, O. Jaekel, J. Debus
Journal: Journal of Clinical Oncology (2010)

e16010 Background: Adenoid cystic carcinomas (ACC's) are rare salivary gland tumors. Conventional RT treatment results are still not satisfactory due to relative radioresistance of these tumors. Modern RT techniques combined with heavy ion RT are applied in the current concept due to higher biological effectiveness of carbon ions (C12). This prospective study assesses clinical outcome and toxicity after a combined treatment approach of IMRT and C12 boost. Methods: Patients (pts) with histological confirmed, advanced ACC's (primary and recurrent tumors) after subtotal resection/ inoperable disease were treated according to protocol. IMRT was delivered to the PTV to a median dose of 54 Gy, (2 Gy/ fx). The GTV was treated with C12 carbon ions to a median dose of 18 GyE (6 fx à 3GyE), overall total dose 72 GyE. The primary end point was local control (LC), secondary end points were toxicity (CTCAE v 3.0) and overall survival (OS). Results: 57 pts (25 male), were included:, median age 52a [27-74], median follow up 47 mo [12 – 120 mo], 1 pt lost to follow up. All patients received the carbon ions as planned, median IMRT dose was 54 Gy [32,4 – 54 Gy]. 8 tumors were located in the parotid gland, 51 tumors originated from small salivary glands (base of skull/nasopharynx: 29; paranasal sinus/maxilla: 17; oropharynx: 5). According to TNM (6th edition) 87.5% of pts had T4, 12,5% T2 or T3 disease. 28% of the pts received RT alone, 72% of pts had subtotal resection. 11 pts experienced local relapse, hence the actuarial LC at 5a is 82%. Actuarial OS and disease-free survival at 5a is 78% and 64.5% respectively. Six pts developed distant metastasis, in 3 pts had a local relapse outside the treatment volume. Grade 1 and 2 late toxicity was seen in 37/57 pts (65%): xerostomia (25 pts), reduction of hearing (12 pts), paresthesia (9 pts) headaches (8 pts), dizziness (4 pts), dysphagia (1 pt). No Grade 3 or higher late toxicity was observed. Conclusions: Combination of IMRT and heavy ion (C12) treatment for locally advanced ACC's resulted in high overall survival rates. Toxicities proved to be moderate. To improve local control, carbon ion dose should probably be increased in this concept. No significant financial relationships to disclose.
NDI-010976, A Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: A Phase 1 Single Ascending Dose Study in Healthy Volunteers
Authors: W.F. Westlin, G. Harriman, H.J. Harwood, R. Kapeller, S. Lennon, W. Miao, K. Stiede, T. Schmalbach
Journal: Journal of Hepatology (2016)
Co-release of dicloxacillin and thioridazine from catheter material containing an interpenetrating polymer network for inhibiting device-associated Staphylococcus aureus infection
Authors: Michael Stenger, Kasper Klein, Rasmus B. Grønnemose, Janne K. Klitgaard, Hans J. Kolmos, Jes S. Lindholt, Martin Alm, Peter Thomsen, Thomas E. Andersen
Journal: Journal of Controlled Release (2016)
Impact of Jak2V617F Mutational Status on Essential Thrombocythemia: An Assessment of Thrombotic Risk Factors on 218 Patients
Authors: Anna Rita Scortechini, Serena Rupoli, Lisa Albani, Simonetta Mulattieri, Paola Picardi, Lidia Da Lio, Berardinelli Eleonora, Simona Tomassetti, Lucia Canafoglia, Pietro Leoni
Journal: Blood (2010)
Obeticholic Acid Accelerates Liver Regeneration in a Rabbit Model of Portal Vein Embolization
Authors: F.G. Schaap, P.B. Olthof, C. Van Himbeeck, F. Huisman, K.P. Van Lienden, R.F. Van Golen, M. Heger, J. Verheij, I.A. Leclercq, P.L. Jansen, T.M. Van Gulik, S.W. Olde Damink
Journal: Journal of Hepatology (2016)
Multicenter Randomized Controlled Trial of Switching to Tenofovir Disoproxil Fumarate Monotherapy in Lamivudine-Resistant Chronic Hepatitis B Patients with Undetectable Hbv Viral Load under Lamivudine/Adefovir Add-On Therapy: Interim Analysis
Authors: Y.-H. Huang, M.-L. Yu, C.-Y. Peng, J.-J. Chen, C.-Y. Chen, C.-W. Su, W.-Y. Lin, H.-C. Lai, Y.-J. Wang, C.-Y. Dai, W.-L. Chuang, H.-C. Lin
Journal: Journal of Hepatology (2016)
Abciximab improves both epicardial flow and myocardial reperfusion in ST elevation myocardial infarction: a TIMI 14 analysis
Authors: de, emos, Ja, EM Antman, CM Gibson, CH McCabe, RP Giugliano, SA Murphy, MJ Frey, WR Van der, Frans Van de Werf, E Braunwald
Journal: Circulation (1999)
Evaluation of the hedgehog pathway as a therapeutic target for preventing the progress to invasive-stage from noninvasive-stage breast cancer.
Authors: M. Sozaki, M. Kubo, M. Kai, C. Kameda, H. Tanaka, H. Onishi, M. Nakamura, M. Tanaka, M. Katano
Journal: Journal of Clinical Oncology (2010)

10601 Background: The hedgehog (Hh) pathway plays a crucial role in the growth and patterning during embryonic development. We have shown that Hh pathway is constitutively activated in invasive ductal carcinoma (IDC) and could be a new therapeutic target for the invasive-type of breast cancer. Purpose: We investigate a possibility that Hh pathway is also a therapeutic target for ductal carcinoma in situ (DCIS). Methods: Total 138 tissues from 62 cases of IDC, 50 cases of DCIS and 26 cases of benign breast tumors (BBT), which were surgically resected in Department of Surgery and Oncology in Kyushu University from 2001 to 2008, were used in this study. The expressions of Hh-related molecules including Shh, Ptch1 and Gli1 were determined by immunohitochemistry. Expressions of Hh-related molecules were also partly examined by real-time PCR using laser capture microdissection technique. The degree of Hh pathway activation was estimated by the ratio of nuclear translocation of Gli1. Results: In immunohistochemistry; 1)Positivity of Shh, Ptch1 and Gli1 were 98.4%, 92.0%, and 95.2% in IDC. Those were 24.0%, 32.0%, and 24.0% in DCIS but were less than 10% in BBT. 2) Degree of Hh pathway activation in IDC was significantly higher (40.95 ± 19.00%) than that in DCIS (12.28 ± 13.80%) and BBT (1.73 ± 2.39%). In real-time PCR; Expressions of Hh-related molecules in IDC and DCIS were higher than those in BBT (p < 0.01). Conclusions: Data suggest that Hh pathway contributes to the progress to IDC from DCIS. Thus, Hh pathway could be a useful therapeutic target for preventing the progress to invasive stage from non-invasive stage of breast cancer. No significant financial relationships to disclose.
T<scp>ranslational</scp> A<scp>dvances</scp> <scp>in</scp> <scp>the</scp> F<scp>ield</scp> <scp>of</scp> P<scp>ulmonary</scp> H<scp>ypertension</scp>.Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than “miR” Words
Authors: Hyung J. Chun, Sébastien Bonnet, Stephen Y. Chan
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).
Authors: W. Janni, J. V. Álvarez, C. A. Papadimitriou, B. Karaszewska, W. Wiest, M. L. Lim, A. Das-Gupta
Journal: Journal of Clinical Oncology (2010)

TPS135 Background: Lapatinib (L), a dual kinase inhibitor of EGFR and ErbB2, is approved in the treatment of metastatic ErbB2+ breast cancer in combination with capecitabine (C) following progression after trastuzumab, anthracylines, and taxanes. Vinorelbine (V) is an important chemotherapy option in this setting, and multiple phase II trials have been conducted in combination with trastuzumab. The combination of L+V has been studied in two phase I trials, but no phase II trials have completed. Furthermore, treatment with L following progression on L remains an unanswered question. Methods: A randomized, open-label, multicentre, phase II study (LAP112620, VITAL) is currently recruiting in over 20 centres in 5 countries to determine the efficacy and safety of L with either V or C in women with ErbB2 overexpressing MBC. 105 patients (currently 5) with disease progression who have received no more than one chemotherapeutic regimen in the metastatic setting will be randomized 2:1 to either Arm A: L 1250 mg orally once daily (QD) continuously plus V 20 mg/m2 intravenously on days 1 and 8, every third week, or Arm B:L 1250 mg orally QD continuously plus C 2000 mg/m2/day orally in 2 doses 12 hours apart on days 1-14 every third week. The primary endpoint is progression-free survival. As this phase II dose selection was based on two ongoing Phase I trials, an interim safety cohort (n=30) is employed with prospectively determined stopping rules for the L+V arm based on clinically-acceptable limits for febrile neutropenia (5%) and Grade 4 neutropenia (20%). Utilizing 95% confidence intervals, these limits may be exceeded with 4 events in 20 patients (20%) for febrile neutropenia and 9 events in 20 (45%) patients for Grade 4 neutropenia. Additionally, a sub-study will evaluate 24 hour V pharmacokinetics with and without concurrent L. For patients who progress while receiving L in this study, an optional cross-over phase to switch chemotherapy (V→C or C→V) with continued L will allow further exploration of the efficacy and safety of L following progression. Recruitment update will be presented. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline, Pierre Fabre Medicament, Roche GlaxoSmithKline, Pierre Fabre Medicament, Roche
Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems
Authors: Guopei Luo, Ammar Javed, Jonathan R. Strosberg, Kaizhou Jin, Yu Zhang, Chen Liu, Jin Xu, Kevin Soares, Matthew J. Weiss, Lei Zheng, Christopher L. Wolfgang, Mauro Cives, Joyce Wong, Wei Wang, Jian Sun, Chenghao Shao, Wei Wang, Huangying Tan, Jie Li, Quanxing Ni, Lin Shen, Minhu Chen, Jin He, Jie Chen, Xianjun Yu
Journal: Journal of Clinical Oncology (2016)

Purpose The European Neuroendocrine Tumor Society (ENETS) and the American Joint Committee on Cancer (AJCC) staging classifications are two widely used systems in managing pancreatic neuroendocrine tumors. However, there is no universally accepted system. Methods An analysis was performed to evaluate the application of the ENETS and AJCC staging classifications using the SEER registry (N = 2,529 patients) and a multicentric series (N = 1,143 patients). A modified system was proposed based on analysis of the two existing classifications. The modified system was then validated. Results The proportion of patients with AJCC stage III disease was extremely low for both the SEER series (2.2%) and the multicentric series (2.1%). For the ENETS staging system, patients with stage I disease had a similar prognosis to patients with stage IIA disease, and patients with stage IIIB disease had a lower hazard ratio for death than did patients with stage IIIA disease. We modified the ENETS staging classification by maintaining the ENETS T, N, and M definitions and adopting the AJCC staging definitions. The proportion of patients with stage III disease using the modified ENETS (mENETS) system was higher than that of the AJCC system in both the SEER series (8.9% v 2.2%) and the multicentric series (11.6% v 2.1%). In addition, the hazard ratio of death for patients with stage III disease was higher than that for patients with stage IIB disease. Moreover, statistical significance and proportional distribution were observed in the mENETS staging classification. Conclusion An mENETS staging classification is more suitable for pancreatic neuroendocrine tumors than either the AJCC or ENETS systems and can be adopted in clinical practice.
Assessing Mechanisms of Ketoconazole and Amiodarone Induced Steatohepatitis in an Organotypic Human Primary Hepatocyte Liver Model
Authors: R. Figler, S. Marukian, M. Collado, D. Manka, M. Lawson, A. Mackey, B. Blackman, B. Wamhoff, A. Dash
Journal: Journal of Hepatology (2016)
Nucleos(T)Ide Analogue Treatment for Immune Tolerant Phase of Chronic Hepatitis B Patients Prolongs Overall Survival and Reduces the Risk of Hepatocellular Carcinoma and Cirrhosis: A Real-Life Study
Authors: Y. Chang, J.-H. Lee, J.Y. Nam, H. Ahn, H. Cho, Y. Cho, Y.Y. Cho, J.-J. Yoo, M. Lee, D.H. Lee, E.J. Cho, S.J. Yu, Y.J. Kim, J.-H. Yoon
Journal: Journal of Hepatology (2016)
Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.
Authors: Claire Fabre, Claude Gardin, Rose-Marie Mbida, Bruno Quesnel, François Dreyfus, Françoise Isnard, Lionel Mannone, Laurence Legros, Thomas Prebet, Norbert Vey, Odile Beyne-Rauzy, Florence Dalbies, Stéphane Cheze, Jacques Delaunay, Christophe Fruchart, Anne Marfaing-Koka, Aspasia Stamatoullas, Dominique Bordessoule, Nathalie Cambier, Jérôme Cornillon, Caroline Dartigeas, Béatrice Delmas-Marsalet, Pierre Fenaux
Journal: Blood (2007)
Timing of Initiation of Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Authors: Paul J. Young, Rinaldo Bellomo, Giovanni Landoni
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
S104 Factors affecting sensitising EGFR mutation rate and cell type in stage IIIB/IV lung cancer: Abstract S104 Table 1
Authors: MPT Kennedy, JA Quinn, AR Biswas, A Rothwell, A Scally, L Cheyne, MEJ Callister
Journal: Thorax (2015)

<h3>Introduction</h3> Treatments for advanced lung cancer in patients with a poor performance status are limited. Such patients (PS 3–4) may not be suitable for chemotherapy for NSCLC, but may benefit from chemotherapy if SCLC is confirmed or treatment with an EGFR-TKI if an EGFR sensitising mutation (EGFR-sm) is detected. Estimates of the likelihood of detecting these two subtypes will enable patients to make informed decisions about undergoing biopsy confirmation. <h3>Aim</h3> To analyse patient factors that affect the frequency of sensitising EGFR mutations and cell types in patients with stage IIIB/IV lung cancer. <h3>Method</h3> Retrospective review of an electronic database of stage IIIB/IV lung cancer patients with known cell type from 2008- 2013 where a quantified smoking history was available. Where EGFR testing was not performed, the estimated prevalence of EGFR-sm was extrapolated from those patients tested according to cell type. Patients with small cell and large cell lung cancer were presumed to be EGFR wild type. <h3>Results</h3> 1033 were identified who fulfilled the inclusion criteria. Cell types were as follows: Adenocarcinoma 31.2%, Squamous Cell 23.5%, Small Cell 22.7%, NSCLC NOS 16.2% and Large Cell 6.4%. Of 348 (33.7%) undergoing genetic testing, EGFR-sm were found in 39 (11.2%) patients. These included 32 of 241 (13.3%) adenocarcinoma, 6 of 80 (7.5%) NOS and 1 of 27 (3.7%) squamous cell. The prevalence of EGFR-sm was estimated for the 384 patients with Adenocaricinoma, NOS and Squamous Cell Carcinoma who were not tested. Table 1 shows the effect of age and pack year smoking history on EGFR mutation status and cell type. Logistic regression analysis shows increasing pack years (p &lt; 0.001) and younger age (p = 0.004) are associated with a lower rate of sensitising EGFR mutations. Increasing pack years is associated with a higher frequency of small cell cancers, but this is not affected by age. <h3>Conclusion</h3> Smoking status significantly impacts the likelihood of detecting both EGFR-sm and SCLC, whereas age alters the likelihood of EGFR-sm alone. These data may allow a more informed discussion regarding the likelihood of detecting an actionable result in patients with advanced lung cancer with poor performance when discussing options for biopsy.
Pan-Genotypic Evaluation of AL-335, a Clinical Stage Uridine Analogue Inhibitor of Hepatitis C Virus Polymerase
Authors: J. Deval, A. Fung, I. Behera, Z. Jin, A. Stoycheva, L.M. Blatt, G. Wang, N. Dyatkina, M. Prhavc, J.A. Symons, D.B. Smith, L. Beigelman
Journal: Journal of Hepatology (2016)
Altered Liver Regeneration after Partial Hepatectomy in Pml-Knockout Mice
Authors: D.F. Ramos, J. Moreno-Cáceres, S.L. Sepulveda, P.C. Ilisso, V.G. de Juan, P.F. Tussy, F. Lopitz-Otsoa, L. Barbier-Torres, I. Zubiete-Franco, P. Iruzubieta, T. Cardoso, D. Mestre, N. Beraza, P. Aspichueta, S.C. Lu, J.M. Mato, P.P. Pandolfi, A. Carracedo, I. Fabregat, M. Varela-Rey, M.L. Martinez-Chantar
Journal: Journal of Hepatology (2016)